Avastin is the first biologic medicine to receive a CHMP positive opinion for the most difficult to treat form of ovarian cancer.
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Avastin® (bevacizumab) in combination with chemotherapy as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. Ovarian cancer has the highest mortality rate of all gynaecological cancers. Of the 230,000 women diagnosed worldwide each year many will have advanced disease that will return after initial treatment.
“Women with platinum-resistant ovarian cancer have limited medicines available for their difficult disease,” said Sandra Horning M.D., Chief Medical Officer and Head, Global Product Development. “EU approval of Avastin for platinum-resistant ovarian cancer would be an important step in helping these women live longer without their disease progressing, and we look forward to receiving the final decision from the European Commission in the coming months.”
Source: Roche
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More